Income Statement BriaCell Therapeutics Corp. Nasdaq

Stocks

BCTX

CA1079303071

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-20 EDT			5-day change	1st Jan Change
3.930 ^USD	-0.76%		+14.24%	-44.73%

08-05	BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study	MT
08-05	Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer	CI

75bb35a77.aF7oJhWpqf2jtG9-IUC2ZLgejZrDW4nuikP5C4lkDa8.EGaRRDjC3MnF9z4ZGHTjKMJfu8-IFcyr2xTKM-c0fsAMKqQffcXGisn9Og

Published financial data: BRIACELL THERAPEUTICS CORP.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Selling General & Admin Expenses, Total	3.72M	7.27M	8.51M	6.65M	6.39M
Stock-Based Compensation (IS)	1.97M	-	-	-	-
R&D Expenses	1.29M	8.02M	14.76M	26.68M	20.81M
Other Operating Expenses, Total	6.97M	15.29M	23.27M	33.33M	27.2M
Operating Income	-6.97M	-15.29M	-23.27M	-33.33M	-27.2M
Interest Expense, Total	-46.1K	-979	-	-	-36.98K
Interest And Investment Income	3.15K	137K	891K	288K	120K
Net Interest Expenses	-42.95K	136K	891K	288K	82.98K
Income (Loss) On Equity Invest.	-	-	-	-107K	-224K
Currency Exchange Gains (Loss)	-2.18M	-30.73K	-40.87K	-25.45K	-24.94K
Other Non Operating Income (Expenses)	8.97M	-11.65M	2.12M	28.24M	758K
EBT, Excl. Unusual Items	-227K	-26.84M	-20.3M	-4.93M	-26.61M
Gain (Loss) On Sale Of Investments	-	-	-	-	56.47K
Other Unusual Items	-201K	-	-	-	-
EBT, Incl. Unusual Items	-428K	-26.84M	-20.3M	-4.93M	-26.56M
Earnings From Continuing Operations	-428K	-26.84M	-20.3M	-4.93M	-26.56M
Net Income to Company	-428K	-26.84M	-20.3M	-4.93M	-26.56M
Minority Interest	-	-	-	140K	244K
Net Income - (IS)	-428K	-26.84M	-20.3M	-4.79M	-26.31M
Net Income to Common Incl Extra Items	-428K	-26.84M	-20.3M	-4.79M	-26.31M
Net Income to Common Excl. Extra Items	-428K	-26.84M	-20.3M	-4.79M	-26.31M
Per Share Items
Net EPS - Basic	-14.22	-259.83	-194.97	-43.68	-62.19
Basic EPS - Continuing Operations	-14.22	-259.83	-194.97	-43.68	-62.19
Basic Weighted Average Shares Outstanding	30.13K	103K	104K	110K	423K
Net EPS - Diluted	-14.22	-259.83	-194.97	-43.68	-62.19
Diluted EPS - Continuing Operations	-14.22	-259.83	-194.97	-43.68	-62.19
Diluted Weighted Average Shares Outstanding	30.13K	103K	104K	110K	423K
Normalized Basic EPS	-4.71	-162.39	-121.86	-26.82	-38.73
Normalized Diluted EPS	-4.71	-162.39	-121.86	-26.82	-38.73
Supplemental Items
EBITDA	-6.96M	-15.27M	-23.26M	-33.25M	-27.1M
EBITA	-6.96M	-15.27M	-23.26M	-33.31M	-27.19M
EBIT	-6.97M	-15.29M	-23.27M	-33.33M	-27.2M
EBITDAR	-6.92M	-	-22.68M	-32.75M	-26.64M
Normalized Net Income	-142K	-16.77M	-12.69M	-2.94M	-16.39M
Interest on Long-Term Debt	40.67K	979	-	-	-
Supplemental Operating Expense Items
General and Administrative Expenses	3.68M	7.27M	7.94M	6.15M	5.93M
Research And Development Expense From Footnotes	1.32M	8.02M	15.34M	27.18M	21.27M
Net Rental Expense, Total	39.97K	-	579K	496K	457K
Imputed Operating Lease Interest Expense	68.28K	-	-	-	-
Imputed Operating Lease Depreciation	-28.31K	-	-	-	-
Stock-Based Comp., R&D Exp. (Total)	-	436K	1.07M	735K	120K
Stock-Based Comp., G&A Exp. (Total)	-	2.64M	1.12M	1.07M	657K
Stock-Based Comp., Other (Total)	1.97M	-	-	-	-
Total Stock-Based Compensation	1.97M	3.07M	2.19M	1.8M	777K

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	57.27M	41.04M	21.25M	862K	10.49M
Short Term Investments	-	-	-	-	7.37M
Total Cash And Short Term Investments	57.27M	41.04M	21.25M	862K	17.87M
Other Receivables	12.57K	24.1K	18.87K	736K	-
Total Receivables	12.57K	24.1K	18.87K	736K	-
Prepaid Expenses	517K	1.28M	5.68M	2.06M	2.06M
Total Current Assets	57.8M	42.35M	26.95M	3.65M	19.93M
Gross Property Plant And Equipment	-	-	-	457K	457K
Accumulated Depreciation	-	-	-	-68.63K	-160K
Net Property Plant And Equipment	-	-	-	388K	297K
Long-term Investments	2	2	2	418K	524K
Other Intangibles, Total	246K	230K	215K	200K	185K
Other Long-Term Assets, Total	-	-	-	1.21M	718K
Total Assets	58.04M	42.58M	27.16M	5.87M	21.65M
Liabilities
Accounts Payable, Total	508K	463K	1.12M	7.17M	3.28M
Accrued Expenses, Total	48.53K	478K	678K	290K	694K
Short-term Borrowings	-	-	-	-	-
Other Current Liabilities	-	-	-	-	-
Total Current Liabilities	557K	941K	1.8M	7.46M	3.98M
Long-Term Debt	25.99K	-	-	-	-
Unearned Revenue Non Current	-	-	-	-	-
Other Non Current Liabilities	199K	31.31M	29.14M	1.1M	338K
Total Liabilities	782K	32.25M	30.94M	8.56M	4.32M
Common Stock, Total	54.78M	65.59M	69.59M	72.17M	102M
Additional Paid In Capital	-	5.23M	-	-	-
Retained Earnings	-15.75M	-60.35M	-80.65M	-85.44M	-112M
Comprehensive Income and Other	18.23M	-139K	7.28M	10.89M	27.9M
Total Common Equity	57.26M	10.33M	-3.78M	-2.38M	17.88M
Minority Interest	-	-	-	-303K	-547K
Total Equity	57.26M	10.33M	-3.78M	-2.68M	17.33M
Total Liabilities And Equity	58.04M	42.58M	27.16M	5.87M	21.65M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	102K	103K	107K	122K	1.88M
ECS Total Common Shares Outstanding	102K	103K	107K	122K	1.88M
Book Value / Share	562.51	99.84	-35.45	-19.54	9.49
Tangible Book Value	57.02M	10.1M	-3.99M	-2.58M	17.7M
Tangible Book Value Per Share	560.09	97.61	-37.47	-21.18	9.39
Total Debt	25.99K	0	0	0	0
Net Debt	-57.24M	-41.04M	-21.25M	-862K	-17.87M
Debt Equivalent Oper. Leases	320K	-	4.63M	3.97M	3.66M
Minority Interest, Total (Incl. Fin. Div)	-	-	-	-303K	-547K
Equity Method Investments, Total	-	-	-	418K	524K
Account Code - Inventory Valuation	-	-	3	3	3
Machinery, Total	-	-	-	457K	457K
Full Time Employees	5	-	16	-	-
Part Time Employees	1	-	-	-	-

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Net Income	-428K	-26.84M	-20.3M	-4.79M	-26.31M
Depreciation & Amortization - CF	-	-	-	68.63K	91.36K
Amortization of Goodwill and Intangible Assets - (CF)	15.26K	15.27K	15.27K	15.27K	15.27K
Depreciation & Amortization, Total	15.26K	15.27K	15.27K	83.9K	107K
(Gain) Loss on Sale of Investments - (CF)	-	-	-	-	-
(Income) Loss On Equity Investments - (CF)	-	-	-	107K	224K
Stock-Based Compensation (CF)	1.97M	3.07M	2.19M	1.8M	777K
Other Operating Activities, Total	-7.02M	11.66M	-2.12M	-28.38M	-1.06M
Change In Accounts Receivable	9.94K	-11.53K	5.23K	-733K	734K
Change In Accounts Payable	-2.19M	249K	660K	6.05M	-3.89M
Change in Other Net Operating Assets	-101K	-629K	-4.2M	1.74M	1.25M
Cash from Operations	-7.75M	-12.48M	-23.74M	-24.13M	-28.17M
Capital Expenditure	-	-	-	-457K	-
Investment in Marketable and Equity Securities, Total	-	-	-	-225K	-7.65M
Cash from Investing	-	-	-	-682K	-7.65M
Short Term Debt Issued, Total	216K	-	-	-	-
Total Debt Issued	216K	-	-	-	-
Short Term Debt Repaid, Total	-549K	-	-	-	-
Total Debt Repaid	-549K	-	-	-	-
Issuance of Common Stock	54.24M	6.51M	4M	4.42M	45.45M
Repurchase of Common Stock	-	-10.17M	-47.29K	-	-
Other Financing Activities, Total	11.08M	-80.69K	-	-	-
Cash from Financing	65M	-3.74M	3.95M	4.42M	45.45M
Foreign Exchange Rate Adjustments	-	-	-	-	-
Net Change in Cash	57.25M	-16.23M	-19.79M	-20.39M	9.63M
Supplemental Items
Levered Free Cash Flow	-5.85M	-6.86M	-15.87M	-10.83M	-18.89M
Unlevered Free Cash Flow	-5.82M	-6.86M	-15.87M	-10.83M	-18.87M
Change In Net Working Capital	3.45M	391K	3.53M	-8.57M	2.75M
Net Debt Issued / Repaid	-333K	-	-	-	-

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-14.88	-18.99	-41.71	-126.11	-123.56
Return on Total Capital	-16.11	-50.26	-444.01	644.72	-232.14
Return On Equity %	-1.6	-141.25	-619.75	152.63	-362.56
Return on Common Equity	-1.6	-141.25	-619.75	155.58	-339.54
Short Term Liquidity
Current Ratio	103.81	45	14.96	0.49	5.01
Quick Ratio	102.88	43.64	11.81	0.21	4.49
Operating Cash Flow to Current Liabilities	-13.91	-13.27	-13.18	-3.23	-7.08
Long Term Solvency
Total Debt/Equity	0.05	-	-	-	-
Total Debt / Total Capital	0.05	-	-	-	-
LT Debt/Equity	0.05	-	-	-	-
Long-Term Debt / Total Capital	0.05	-	-	-	-
Total Liabilities / Total Assets	1.35	75.74	113.91	145.72	19.93
EBIT / Interest Expense	-151.29	-15.62K	-	-	-735.68
EBITDA / Interest Expense	-150.95	-15.6K	-	-	-732.8
(EBITDA - Capex) / Interest Expense	-150.95	-15.6K	-	-	-732.8
Total Debt / EBITDA	-0	-	-	-	-
Net Debt / EBITDA	8.23	2.69	0.91	0.03	0.66
Total Debt / (EBITDA - Capex)	-0	-	-	-	-
Net Debt / (EBITDA - Capex)	8.23	2.69	0.91	0.03	0.66
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	77.32	119.42	52.27	42.95	-18.49
EBITA, 1 Yr. Growth %	77.32	119.42	52.27	43.25	-18.39
EBIT, 1 Yr. Growth %	77.02	119.16	52.22	43.22	-18.38
Earnings From Cont. Operations, 1 Yr. Growth %	-89.36	94.26	-24.35	-75.71	438.5
Net Income, 1 Yr. Growth %	-89.36	94.26	-24.35	-76.4	449.14
Normalized Net Income, 1 Yr. Growth %	-94.26	96.27	-24.35	-76.81	457.03
Diluted EPS Before Extra, 1 Yr. Growth %	-	-43.34	-24.96	-77.6	42.37
Net Property, Plant and Equip., 1 Yr. Growth %	-	-	-	-	-23.53
Total Assets, 1 Yr. Growth %	11.01K	-26.65	-36.2	-78.38	268.68
Tangible Book Value, 1 Yr. Growth %	-1.58K	-63.18	-139.53	-35.32	-785.32
Common Equity, 1 Yr. Growth %	-1.69K	-62.67	-136.57	-36.93	-850.54
Cash From Operations, 1 Yr. Growth %	512.03	61.08	90.2	1.61	16.76
Levered Free Cash Flow, 1 Yr. Growth %	-2.87K	17.57	131.39	-31.72	74.39
Unlevered Free Cash Flow, 1 Yr. Growth %	-2.64K	18.56	131.41	-31.72	74.17
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	17.39	97.29	82.79	47.54	7.94
EBITA, 2 Yr. CAGR %	17.39	97.29	82.79	47.69	8.12
EBIT, 2 Yr. CAGR %	17.34	97	82.65	47.65	8.12
Earnings From Cont. Operations, 2 Yr. CAGR %	-69.85	158.24	21.22	-57.13	14.37
Net Income, 2 Yr. CAGR %	-69.85	158.24	21.22	-57.75	13.84
Normalized Net Income, 2 Yr. CAGR %	-78.8	160.33	21.85	-58.12	13.65
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	-34.79	-59	-43.52
Total Assets, 2 Yr. CAGR %	1.04K	802.85	-31.59	-62.86	-10.72
Tangible Book Value, 2 Yr. CAGR %	668.75	61.78	-61.85	-49.43	110.54
Common Equity, 2 Yr. CAGR %	811.86	69.45	-63.05	-51.97	117.58
Cash From Operations, 2 Yr. CAGR %	36.68	214.04	75.04	39.01	8.92
Levered Free Cash Flow, 2 Yr. CAGR %	55.87	470.27	64.94	25.7	9.12
Unlevered Free Cash Flow, 2 Yr. CAGR %	56.01	446.85	65.64	25.7	9.05
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	20.5	44.62	80.97	68.41	21.06
EBITA, 3 Yr. CAGR %	20.5	44.62	80.97	68.52	21.2
EBIT, 3 Yr. CAGR %	20.45	44.52	80.77	68.43	21.18
Earnings From Cont. Operations, 3 Yr. CAGR %	-53.79	78.58	71.51	-29.06	-0.35
Net Income, 3 Yr. CAGR %	-53.79	78.58	71.51	-29.74	-0.66
Normalized Net Income, 3 Yr. CAGR %	-61.6	74.45	72.43	-29.92	-0.77
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-	-54.33	-37.91
Total Assets, 3 Yr. CAGR %	189.7	357.49	273.26	-53.4	-20.18
Tangible Book Value, 3 Yr. CAGR %	333.41	118.75	1.14	-54.51	20.56
Common Equity, 3 Yr. CAGR %	287.08	146.61	1.64	-55.84	20.07
Cash From Operations, 3 Yr. CAGR %	24.9	44.39	165.7	46.01	31.16
Levered Free Cash Flow, 3 Yr. CAGR %	26.63	41.75	322.19	22.93	40.19
Unlevered Free Cash Flow, 3 Yr. CAGR %	26.57	42.06	310.56	23.27	40.14
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	31.87	43.49	43.89	45.78	47.18
EBITA, 5 Yr. CAGR %	31.86	43.49	43.89	45.84	47.28
EBIT, 5 Yr. CAGR %	31.91	43.52	43.81	45.76	47.18
Earnings From Cont. Operations, 5 Yr. CAGR %	-24.76	60.59	37.61	0.91	45.84
Net Income, 5 Yr. CAGR %	-24.76	60.59	37.61	0.33	45.58
Normalized Net Income, 5 Yr. CAGR %	-33.55	60.59	39.78	-1.42	45.95
Total Assets, 5 Yr. CAGR %	131.37	92.97	64.38	67.55	110.62
Tangible Book Value, 5 Yr. CAGR %	133.33	69.14	43.16	21.76	35.61
Common Equity, 5 Yr. CAGR %	133.53	69.9	32.18	28.17	37.81
Cash From Operations, 5 Yr. CAGR %	43.89	52.92	44.5	42.22	85.99
Levered Free Cash Flow, 5 Yr. CAGR %	56.86	65.67	42.18	35.1	145.73
Unlevered Free Cash Flow, 5 Yr. CAGR %	56.7	65.67	42.28	35.27	141.59